The study presents a novel mouse model for spontaneous aortic dissection (AD), developed by introducing a patient-derived FBN1 gene variant (Gly234Asp) using CRISPR/Cas9. This mutation, identified in a family with nonsyndromic AD, leads to early-onset, rapidly progressing aortic dissection in homozygous mutant mice, with a 50% mortality rate by five weeks of age. The mutant mice exhibit multiple intimomedial tears in the ascending aorta, mimicking human pathology. The research identifies early abnormalities in endothelial cells (ECs), such as misalignment with blood flow and upregulation of adhesion molecules (VCAM-1 and ICAM-1), contributing to immune cell recruitment.
This systematic review and meta-analysis evaluates the effectiveness of pulmonary artery pressure (PAP)-guided management using the CardioMEMS Heart Failure System in patients with heart failure (HF) outside the controlled settings of randomized clinical trials. The study aims to assess real-world evidence regarding the system’s impact on key clinical outcomes, particularly heart failure hospitalizations (HFHs), functional status, and quality of life.
The article discusses the evolving yet critical role of basal insulin (BI) in managing type 2 diabetes mellitus (T2DM) in the era of newer glucose-lowering agents such as GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2is). While these newer therapies offer advantages like minimal titration, weight reduction, and cardiovascular/renal benefits, BI continues to serve as a vital therapeutic tool, particularly when other medications fail to maintain adequate glucose control or in scenarios like metabolic stress, pregnancy, latent autoimmune diabetes (LADA), or comorbidity-driven limitations.
The study investigates the long-term cardiovascular and mortality risks associated with adult-onset type 1 diabetes (T1D), especially in individuals diagnosed at age 40 or older, using data from over 10,000 people with T1D in Sweden. It compares them with patients with type 2 diabetes (T2D) and over half a million diabetes-free controls, tracking outcomes from 2005 to 2022.
The article from the European Heart Journal discusses recent advances in treatments and biomarkers for heart failure (HF), hypertrophic cardiomyopathy (HCM), and familial hypercholesterolaemia (FH), highlighting both clinical trials and emerging research.
